Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Niacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.84 |
| ▸ | APP | P05067 | 1/20 | 0.84 |
| ▸ | GAA | P10253 | 1/20 | 0.84 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.84 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.84 |
| ▸ | F7 | P08709 | 1/20 | 0.57 |
| ▸ | F3 | P13726 | 1/20 | 0.57 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.57 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.57 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.57 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.57 |
| ▸ | KMO | O15229 | 1/20 | 0.56 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacin SCHEMBL28400835 | 0.98 | ALDH1A1 (0.81) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL28400834 | 0.98 | ALDH1A1 (0.81) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL27827804 | 0.98 | ALDH1A1 (0.81) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL31324786 | 0.92 | ALDH1A1 (0.78) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL29349574 | 0.92 | — | — | |
| Niacin SCHEMBL29396199 | 0.92 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL30844065 | 0.92 | — | — | |
| Niacin SCHEMBL3081560 | 0.92 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL1433 | 0.92 | — | — | |
| Niacin SCHEMBL28292236 | 0.92 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | claimed |
| US-20040067890-A1 | Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions | GUPTA SHYAM K (US) | 2004-04-08 | — | — | US | claimed |
| CN-110551748-B | Super-recombinant mycobacterium smegmatis producing nicotinic acid and construction method thereof | 佛山科学技术学院 | 2023-04-25 | — | — | CN | disclosed |
| CN-108424871-A | A kind of the mutation mycobacterium smegmatis and its construction method of secretion niacin | 佛山科学技术学院 | 2018-08-21 | — | — | CN | disclosed |
| CN-108384739-A | A kind of integrated recombinant Mycobacterium smegmatis and its construction method of production niacin | 上海晶诺生物科技有限公司 | 2018-08-10 | — | — | CN | disclosed |
| CN-108359666-A | A kind of nudC genes and its application in terms of preparing niacin | 上海晶诺生物科技有限公司 | 2018-08-03 | — | — | CN | disclosed |
| CN-108330094-A | A kind of the sequestered recombinant Mycobacterium smegmatis and its construction method of production niacin | 上海晶诺生物科技有限公司 | 2018-07-27 | — | — | CN | disclosed |
| CN-1141288-A | Process for preparing nicotinic acid | QINGHUA ZIGUANG UP GEN CORP (CN) | 1997-01-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | CUTA, HIRA, HARS1 | ALDH1A1 1928/4885APP 2342/4885GAA 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.